TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jupiter Neurosciences, Inc. ( (JUNS) ) has provided an announcement.
Jupiter Neurosciences, Inc. announced on July 10, 2025, that it has regained compliance with the Nasdaq’s minimum bid price requirement, after receiving a notice from Nasdaq confirming its stock maintained a closing price of at least $1.00 for thirteen consecutive days from June 18 to July 8, 2025. This compliance ensures that Jupiter’s shares remain listed on the Nasdaq, closing a matter that had posed a potential risk to its market presence.
The most recent analyst rating on (JUNS) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Jupiter Neurosciences, Inc. stock, see the JUNS Stock Forecast page.
More about Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging. It is advancing a therapeutic pipeline targeting central nervous system disorders and rare diseases, and expanding into the consumer longevity market with its Nugevia product line, powered by its proprietary JOTROL formulation.
Average Trading Volume: 432,036
Current Market Cap: $48.66M
See more data about JUNS stock on TipRanks’ Stock Analysis page.